NEXGEL, Inc. (NXGL) is a small-cap healthcare company based in Langhorne, Pennsylvania, that manufactures high-water-content, electron-beam cross-linked hydrogels used in wound care, diagnostics, cosmetics and over-the-counter products, and that now markets regenerative biomaterials such as Biovance and Interfyl through its BioNX Surgical division. In midday trading on Thursday, the stock changed hands at $3.37, down 5.87% from Wednesday's close of $3.58, a decline of $0.21. The direction was clearly negative. The move followed the company's announcement that its quarterly conference call, originally scheduled for the evening of November 19, has been pushed to November 24.
The company said it delayed its third-quarter financial results and corporate update call by two business days, to November 24 at 4:30 p.m. Eastern, noting that its Form 10-Q for the quarter ended September 30 was already filed on November 16. In isolation, a scheduling change is routine. For a company of this size and financial profile, however, postponements are read as a signal of unresolved disclosure or transaction work, particularly since the 10-Q is already public and the call is meant to explain it. Traders treated the delay as a reason to reduce exposure rather than wait for management's commentary.
The quarterly report that the call was meant to discuss showed third-quarter sales of $3.18 million versus $2.93 million a year earlier, but a net loss of $1.11 million compared with $0.653 million. For the first nine months, the net loss reached $5.68 million against $2.03 million. Revenue growth is not translating into profitability, and the company continues to carry going-concern language from its most recent annual audit.
The capital structure adds a further overhang. Noteholders holding roughly $14.1 million of $14.9 million in convertible principal have agreed to convert into equity only if a strategic merger closes, with a conversion price of $5.50 a share set alongside roughly $1.28 million in new stock sold at the same price with $10 warrants. That structure dilutes existing holders at a premium to the current price while leaving the debt outstanding if the transaction fails by the March 2027 outside date. The contemplated combination with Fountainhead LifeSciences and affiliates, including Sequence LifeScience and NVISION Biomedical, is a related-party deal and remains unsigned, so investors are pricing execution risk on two fronts at once.
Turnover has thinned considerably since October, when the post-reverse-split rebound drove one session above 1.4 million shares traded. Recent sessions have run at a fraction of the roughly 114,000-share average, and today's tape was similarly light, which magnifies price movement in a stock with an approximate $11 million market capitalization. No peer or sector-wide catalyst was evident, and the decline was divergent from broad small-cap healthcare sentiment, underscoring that the pressure was company-specific. Technically, the shares slipped below the $3.50 area that had held as the November floor and are trading at their lowest level since the first week of October, with the slide now roughly 20% from the November 11 close of $4.24.
The score runs from 0 to 100, where 0 means no meaningful news and a move that is ordinary for the stock, and 100 means transformative news paired with an extreme, rare price move. NEXGEL earns 17 out of 100. The verified news — a two-business-day delay to a call covering results already filed — is modest measured against an $11 million company, though it lands on a balance sheet already flagged for going-concern doubt. The price action was unremarkable by the stock's own standards: at 5.87%, the decline was about 0.8 times the 7.3% average absolute daily move of the past 60 sessions, and 28 of those sessions produced equal or larger swings. Modest news and routine volatility together produce a low score.
The rescheduled November 24 call is the nearest checkpoint, with management expected to address BioNX Surgical integration, cost savings and liquidity. Investors will also watch for a definitive merger agreement, the conditions attached to the note conversions, and any additional growth capital the company has flagged as possible around a closing. Because the third-quarter 10-Q is already filed, the call carries greater weight than usual as the only forum for forward commentary. Risks include continued cash burn, the possibility that the merger does not close and the notes revert to their original terms, related-party conflict concerns, and the dilutive mechanics of a financing priced well above the current share price.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the list gives investors a concise view of which automated approaches are working right now rather than a static catalogue. Reviewing the current leaders can help you benchmark your own ideas against live, rules-based performance. Visit the Trending AI Robots page to see which bots are leading today.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
NXGL saw its Momentum Indicator move below the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 116 similar instances where the indicator turned negative. In 106 of the 116 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NXGL turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 44 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NXGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for NXGL entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +24.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where NXGL advanced for three days, in 149 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.894) is normal, around the industry mean (4.964). P/E Ratio (-4.730) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.172) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. NXGL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NXGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsOther